ArticleEJNMMI research2021
In vitro proof of concept studies of radiotoxicity from Auger electron-emitter thallium-201.
Article in EJNMMI research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- Bone Radiopharmaceuticals: Evolution from Palliative Therapy to Targeted Precision Oncology and Theranostics.Biology · 2026Review
- Ion Beam Imaging Shows Selective Thallium-201 Uptake in Cell Nuclei: Impact on Cellular Dosimetry and Radiotoxicity of Auger Electron Emitters.Chemical & biomedical imaging · 2026Article
- Advances in radiopharmaceuticals for cancer radiotheranostics: CCK2R targeting as a paradigm for translational innovation.Cancer communications (London, England) · 2025Review
- In Vitro and In Vivo Radiotoxicity and Biodistribution of Thallium-201 Delivered to Cancer Cells by Prussian Blue Nanoparticles.ACS applied materials & interfaces · 2025Article
- Synthesis and Characterization of Thallium-Texaphyrin Nanoparticles and Their Assessment as Potential Delivery Systems for Auger Electron-EmittingMolecular pharmaceutics · 2025Article
- Mechanisms of inclusion of thallium-201 into Prussian blue nanoparticles for nuclear medicine applications.Journal of materials chemistry. B · 2024Article
- A Review on Tumor Control Probability (TCP) and Preclinical Dosimetry in Targeted Radionuclide Therapy (TRT).Pharmaceutics · 2022Review
- Toward Bifunctional Chelators for Thallium-201 for Use in Nuclear Medicine.Bioconjugate chemistry · 2022Article
- Non-invasive radionuclide imaging of trace metal trafficking in health and disease: "PET metallomics".RSC chemical biology · 2022Review
- Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study.Cancers · 2022Article
- Relationship of In Vitro Toxicity of Technetium-99m to Subcellular Localisation and Absorbed Dose.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAuger electron-emitting radionuclides have potential in targeted treatment of small tumors. Thallium-201 (
methodsBreast cancer MDA-MB-231 and prostate cancer DU145 cells were incubated with 200-8000 kBq/mL [
results
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.